419 related articles for article (PubMed ID: 37701916)
21. Metabolic dysfunction-associated fatty liver disease improves detection of high liver stiffness: The Rotterdam Study.
van Kleef LA; Ayada I; Alferink LJM; Pan Q; de Knegt RJ
Hepatology; 2022 Feb; 75(2):419-429. PubMed ID: 34453359
[TBL] [Abstract][Full Text] [Related]
22. Hepatologists' awareness and knowledge toward NAFLD and the familiarity with renaming from NAFLD to MAFLD.
Alem SA; Fouad Y; AbdAllah M; Attia D; Kamal I; Said E; Gomaa A; Abd-Elsalam SM; Gaber Y
Endocr Metab Immune Disord Drug Targets; 2022 Oct; ():. PubMed ID: 36306455
[TBL] [Abstract][Full Text] [Related]
23. A comparison of NAFLD and MAFLD diagnostic criteria in contemporary urban healthy adults in China: a cross-sectional study.
Liu Q; Zhao G; Li Q; Wu W; Zhang Y; Bian H
BMC Gastroenterol; 2022 Nov; 22(1):471. PubMed ID: 36402947
[TBL] [Abstract][Full Text] [Related]
24. MAFLD identifies patients with significant hepatic fibrosis better than NAFLD.
Yamamura S; Eslam M; Kawaguchi T; Tsutsumi T; Nakano D; Yoshinaga S; Takahashi H; Anzai K; George J; Torimura T
Liver Int; 2020 Dec; 40(12):3018-3030. PubMed ID: 32997882
[TBL] [Abstract][Full Text] [Related]
25. Association of metabolic dysfunction-associated fatty liver disease with chronic kidney disease: a Chinese population-based study.
Hu Q; Chen Y; Bao T; Huang Y
Ren Fail; 2022 Dec; 44(1):1996-2005. PubMed ID: 36374233
[TBL] [Abstract][Full Text] [Related]
26. Risk of cardiovascular disease in patients with fatty liver disease as defined from the metabolic dysfunction associated fatty liver disease or nonalcoholic fatty liver disease point of view: a retrospective nationwide claims database study in Japan.
Yoneda M; Yamamoto T; Honda Y; Imajo K; Ogawa Y; Kessoku T; Kobayashi T; Nogami A; Higurashi T; Kato S; Hosono K; Saito S; Nakajima A
J Gastroenterol; 2021 Nov; 56(11):1022-1032. PubMed ID: 34601620
[TBL] [Abstract][Full Text] [Related]
27. Comparative Associations of Nonalcoholic Fatty Liver Disease and Metabolic Dysfunction-Associated Fatty Liver Disease With Coronary Artery Calcification: A Cross-Sectional and Longitudinal Cohort Study.
Sung KC; Yoo TK; Lee MY; Byrne CD; Zheng MH; Targher G
Arterioscler Thromb Vasc Biol; 2023 Mar; 43(3):482-491. PubMed ID: 36727522
[TBL] [Abstract][Full Text] [Related]
28. Nonalcoholic fatty liver disease without overlapping metabolic-associated fatty liver disease and the risk of incident type 2 diabetes.
Cho Y; Chang Y; Ryu S; Wild SH; Byrne CD
Liver Int; 2023 Nov; 43(11):2445-2454. PubMed ID: 37387519
[TBL] [Abstract][Full Text] [Related]
29. Lean-non-alcoholic fatty liver disease increases risk for metabolic disorders in a normal weight Chinese population.
Feng RN; Du SS; Wang C; Li YC; Liu LY; Guo FC; Sun CH
World J Gastroenterol; 2014 Dec; 20(47):17932-40. PubMed ID: 25548491
[TBL] [Abstract][Full Text] [Related]
30. Ethyl glucuronide in hair detects a high rate of harmful alcohol consumption in presumed non-alcoholic fatty liver disease.
Staufer K; Huber-Schönauer U; Strebinger G; Pimingstorfer P; Suesse S; Scherzer TM; Paulweber B; Ferenci P; Stimpfl T; Yegles M; Datz C; Trauner M
J Hepatol; 2022 Oct; 77(4):918-930. PubMed ID: 35605744
[TBL] [Abstract][Full Text] [Related]
31. Comparison of Clinical Characteristics and Outcomes of MAFLD and NAFLD in Chinese Health Examination Populations.
Xu X; Zhou X; Tian T; Ding Y; Yu C; Zhao W; Wang X; Lu J; Guo W; Jiang L; Wang Q; Zhang Q; Song C
J Clin Transl Hepatol; 2023 Aug; 11(4):777-786. PubMed ID: 37408819
[TBL] [Abstract][Full Text] [Related]
32. Correlation of the pediatric metabolic index with NAFLD or MAFLD diagnosis, and serum adipokine levels in children.
Lazo-de-la-Vega-Monroy ML; Preciado-Puga MD; Ruiz-Noa Y; Salum-Zertuche M; Ibarra-Reynoso LD
Clin Res Hepatol Gastroenterol; 2023 May; 47(6):102137. PubMed ID: 37149032
[TBL] [Abstract][Full Text] [Related]
33. Metabolic dysfunction-associated fatty liver disease and the risk of hepatocellular carcinoma.
Song BG; Choi SC; Goh MJ; Kang W; Sinn DH; Gwak GY; Paik YH; Choi MS; Lee JH; Paik SW
JHEP Rep; 2023 Sep; 5(9):100810. PubMed ID: 37538246
[TBL] [Abstract][Full Text] [Related]
34. Comparing the Diagnostic Criteria of MAFLD and NAFLD in the Chinese Population: A Population-based Prospective Cohort Study.
Yu C; Wang M; Zheng S; Xia M; Yang H; Zhang D; Yin C; Cheng N; Bai Y
J Clin Transl Hepatol; 2022 Feb; 10(1):6-16. PubMed ID: 35233368
[TBL] [Abstract][Full Text] [Related]
35. Impact of metabolic factors on risk of cardiovascular disease in nondiabetic metabolic dysfunction-associated fatty liver disease.
Kang MK; Lee YR; Jang SY; Tak WY; Kweon YO; Song JE; Loomba R; Park SY; Park JG
Hepatol Int; 2023 Jun; 17(3):626-635. PubMed ID: 37069419
[TBL] [Abstract][Full Text] [Related]
36. Metabolic-associated fatty liver disease: a selective review of pathogenesis, diagnostic approaches, and therapeutic strategies.
Habibullah M; Jemmieh K; Ouda A; Haider MZ; Malki MI; Elzouki AN
Front Med (Lausanne); 2024; 11():1291501. PubMed ID: 38323033
[TBL] [Abstract][Full Text] [Related]
37. An Observational Data Meta-analysis on the Differences in Prevalence and Risk Factors Between MAFLD vs NAFLD.
Lim GEH; Tang A; Ng CH; Chin YH; Lim WH; Tan DJH; Yong JN; Xiao J; Lee CW; Chan M; Chew NW; Xuan Tan EX; Siddiqui MS; Huang D; Noureddin M; Sanyal AJ; Muthiah MD
Clin Gastroenterol Hepatol; 2023 Mar; 21(3):619-629.e7. PubMed ID: 34871813
[TBL] [Abstract][Full Text] [Related]
38. Comparative study of MAFLD as a predictor of metabolic disease treatment for NAFLD.
Imai J; Takashimizu S; Suzuki N; Ohshinden K; Sawamoto K; Mishima Y; Tsuruya K; Arase Y; Yamano M; Kishimoto N; Yamada C; Inoue N; Moriyama K; Baba A; Suzuki H; Kagawa T; Nishizaki Y
Sci Rep; 2024 Jun; 14(1):13411. PubMed ID: 38862756
[TBL] [Abstract][Full Text] [Related]
39. Cardiovascular and renal burdens of metabolic associated fatty liver disease from serial US national surveys, 1999-2016.
Zhang HJ; Wang YY; Chen C; Lu YL; Wang NJ
Chin Med J (Engl); 2021 Jun; 134(13):1593-1601. PubMed ID: 34091530
[TBL] [Abstract][Full Text] [Related]
40. Association of MAFLD With Diabetes, Chronic Kidney Disease, and Cardiovascular Disease: A 4.6-Year Cohort Study in China.
Liang Y; Chen H; Liu Y; Hou X; Wei L; Bao Y; Yang C; Zong G; Wu J; Jia W
J Clin Endocrinol Metab; 2022 Jan; 107(1):88-97. PubMed ID: 34508601
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
